1. Scrip
  2. >>Business
  3. >>Financing

IPO Update: What A Difference A (Pandemic) Year Makes

COVID-19 Paralyzed Market In Q1 2020 But Fortunes Reversed In 2021

 
• By Mandy Jackson

Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.

IPO (Initial Public Offering) letters hanging from strings
32 biopharma companies went public in the US in Q1, raising $5.2bn and generating an 11% average return • Source: Shutterstock

The market for initial public offerings in the US was vastly different in the first quarter of 2020 than it was during the same period of 2021.

Uncertainty related to COVID-19 shut down global financial markets in Q1 of last year, bringing initial public offerings to a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.